Teva to Launch First Generic for Diclegis
June 27, 2019 – Teva Pharmaceuticals has announced its intention to launch the first generic for Duchesnay’s Diclegis® (doxylamine succinate and pyridoxine hydrochloride delayed-release tablets). The product is approved to treat nausea and vomiting related to pregnancy in women who have not responded to conservative management.
Recommended dosing is two tablets taken daily at bedtime. The dose can be increased to a maximum of four tablets daily (one taken in the morning, one mid-afternoon, and two at bedtime) if symptoms are not adequately controlled. Each tablet contains 10mg of doxylamine succinate and 10mg of pyridoxine hydrochloride.
Teva has not yet released pricing information.